FDA approves tirzepatide for reducing cardiovascular risk in adults with type 2 diabetes - Cardiovascular Business

August 28, 2026 Malcolm Knoll Business

FDA Approves Tirzepatide for Reducing Cardiovascular Risk in Adults with Type 2 Diabetes

Cardiovascular Business

FDA has approved tirzepatide for lowering cardiovascular risk in adults with type 2 diabetes.